Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016301 | 0.93 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2BCYP3A4 | |
| SCHEMBL5022820 | 0.87 | ADORA2A (0.58) | ADORA2AADORA1ADORA3ADORA2BCYP3A4 | |
| SCHEMBL5022206 | 0.86 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2BCYP3A4 | |
| SCHEMBL5016175 | 0.86 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2BCYP3A4 | |
| SCHEMBL5017747 | 0.85 | ADORA2A (0.65) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL5022291 | 0.85 | ADORA2A (0.77) | ADORA2AADORA1ADORA3ADORA2BCYP3A4 | |
| SCHEMBL5016278 | 0.83 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2BPOLB | |
| SCHEMBL5024936 | 0.83 | ADORA2A (0.69) | ADORA2AADORA1ADORA3ADORA2BCYP3A4 | |
| SCHEMBL5022948 | 0.83 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2BPOLB | |
| SCHEMBL5017620 | 0.82 | ADORA2A (0.68) | ADORA2AADORA1ADORA3ADORA2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | claimed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| EP-1697351-A1 | 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058883-A1 | 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.